Schistosomiasis Scholarly Peer-review Journal
Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Symptoms include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected for a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty. The disease is spread by contact with fresh water contaminated with the parasites. These parasites are released from infected freshwater snails. The disease is especially common among children in developing countries, as they are more likely to play in contaminated water. Other high-risk groups include farmers, fishermen, and people using unclean water during daily living. It belongs to the group of helminth infections. Diagnosis is by finding eggs of the parasite in a person's urine or stool. It can also be confirmed by finding antibodies against the disease in the blood. Methods to prevent the disease include improving access to clean water and reducing the number of snails. In areas where the disease is common, the medication praziquantel may be given once a year to the entire group. This is done to decrease the number of people infected, and consequently, the spread of the disease. Praziquantel is also the treatment recommended by the World
Health Organization for those who are known to be infected.
Schistosomiasis affected about 252 million people worldwide in 2015. An estimated 4,400 to 200,000 people die from it each year. The disease is most commonly found in Africa, Asia, and South America. Around 700 million people, in more than 70 countries, live in areas where the disease is common. In tropical countries,
schistosomiasis is second only to
malaria among parasitic diseases with the greatest economic impact.
Schistosomiasis is listed as a neglected tropical disease.
High Impact List of Articles
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
David Doherty, co-founder of 3G doctor
David Doherty
Interview: Clinical Investigation
-
Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1
Gregory M Pastores and Derralynn Hughes
Review: Clinical Trail Outcomes: Clinical Investigation
-
Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1
Gregory M Pastores and Derralynn Hughes
Review: Clinical Trail Outcomes: Clinical Investigation
-
Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1
Gregory M Pastores and Derralynn Hughes
Review: Clinical Trail Outcomes: Clinical Investigation
-
Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1
Gregory M Pastores and Derralynn Hughes
Review: Clinical Trail Outcomes: Clinical Investigation
-
Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1
Gregory M Pastores and Derralynn Hughes
Review: Clinical Trail Outcomes: Clinical Investigation
-
Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1
Gregory M Pastores and Derralynn Hughes
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Insulin degludec in Type 1 diabetes
VS Eligar,S Bain
Review: Clinical Trail Outcomes: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
Relevant Topics in Clinical